Bamlanivimab, a monoclonal antibody-based drug for the treatment of out-of-hospital cases of COVID-19 patients, has been approved by the US Food and Drug Administration (FDA).
The treatment works by attacking the virus and prevents the patient from getting worse.
Dr. Huerta explains in more detail.